Vivadju has prepared a few partnership opportunities to participate in a business that is at an exciting stage of development.

The business involves completing the required testing to demonstrate the efficacy of an adjuvant to eradicate cancer cells both initially and in the event of relapse without the need for chemotherapy and its side effects.

Our inventors have developed and patented an adjuvant using DNA in conjunction with all-trans retinoic acid (ATRA). Trials have already been conducted in malignant mice and these were successful. It is now necessary to proceed to rabbit trials to test toxicity and, if no adverse effects, on to human trials. This activating platform can be applied to different cancers.

With the success of the RNA vaccines against the Covid-19 virus, nucleic acid-based vaccines using a DNA template are now proven to be efficacious and safe.

As part of the next phase, testing will be undertaken on combining the adjuvant with other agents as this could produce commercial options for the adjuvant.

Cancer Relapse is Vivadju’s market

For Hematological Cancers alone: EU + US 2 million Survivors + 0.5 million new cases per year

There are 50 million cancer survivors worldwide today.

A detailed presentation is available for potential partners who would like to understand the background to the opportunity more fully- related to it.

Why Invest?

This immunotherapy strategy has the potential to save and improve the quality of millions of lives and has the potential to generate a substantial return on investment.

With 16.9 Million patients alive with cancer in the US in 2019 and with similar numbers in Europe and 50 million cancer survivors worldwide, the market is potentially worth $ billions.